Avita Medical Appoints Dr. Michael S. Perry to Board of Directors

Avita Medical Appoints Dr. Michael S. Perry to Board of Directors
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) --
02/06/13 -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)
-- VP and Senior Global Program Head, Stem Cell Therapy at Novartis
Pharmaceuticals
-- 25 Years Management Experience in Pharmaceutical and Biotech
Development
-- Substantial Venture Capital Expertise in Life Science Funds
Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX:
AVMXY) today announced that Dr. Michael S. Perry, Vice President and
Senior Global Program Head, Stem Cell Therapy at Novartis
Pharmaceuticals Corp., has been appointed to the company's board of
directors. Dr. Perry has over 25 years of successful
pharmaceutical/biotech management and development experience.
Dalton Gooding, Avita Medical chairman, said, "Michael has
extraordinary biotech and business expertise, and we are delighted
that he is joining Avita's board of directors."
Perry currently serves as Vice President and Senior Global Program
Head, Stem Cell Therapy at Novartis Pharmaceuticals Corp, a US
affiliate of Switzerland-based Novartis AG, a world leader in the
research and development of products to protect and improve health
and well-being with core businesses in pharmaceuticals, vaccines,
consumer health, generics, eye care and animal health.
Dr. Perry, based in the United States, has previously served as the
Global Head of R&D at Baxter Healthcare, President, Cell & Gene
Therapy at Novartis affiliates SyStemix and Genetic Therapy, Inc., VP
Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of
Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO
or CMO at several early stage biotech companies.
From 2005 to 2012, Dr. Perry was a Venture Partner with Bay City
Capital, a California-based venture capital firm managing over US$1.6
billion invested predominantly in life science companies.
"Michael brings a wealth of experience and scientific acumen as well
as the insights that come from running successful large global
divisions and emerging startups. Michael will be a great addition to
our board and I am delighted to be working with him," said Dr William
Dolphin, Avita chief executive officer.
"I am honoured to join the Avita board and work with this exceptional
team," Perry said. "Avita has the potential to make a significant
impact in the field of regenerative medicine and I look forward to
sharing my experiences and contributing to the future direction and
growth at this early stage in the company's history."
In addition to Avita Medical, Dr. Perry currently serves on the board
of two publicly held companies.
ABOUT AVITA MEDICAL LTD.
Avita Medical
(http://www.avitamedical.com/) develops and distributes regenerative
products for the treatment of a broad range of wounds, scars and skin
defects. Avita's patented and proprietary tissue-culture, collection
and application technology provides innovative treatment solutions
derived from a patient's own skin. The company's lead product,
ReCell(R) Spray-On Skin(TM), is used in a wide variety of burns,
chronic wounds, plastic, reconstructive and cosmetic procedures.
ReCell is patented, CE-marked for Europe, TGA-registered in
Australia, and SFDA-cleared in China. ReCell is not available for
sale in the United States; in the US ReCell is an investigational
device limited by federal law to investigational use. An FDA trial on
the safety and efficacy of ReCell is in process.
Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone: +1 838-352-9400
Email: ssung@avitamedical.com
Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone: +1 646-863-6893
Email: jramson@proactivecapitalgroup.com